{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:26:00Z","timestamp":1791606360411,"version":"4.3.4"},"reference-count":150,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Severe adverse systemic drug events occur commonly as a result of treatment of cancer patients. Nephrotoxicity of chemotherapeutic agents remains a significant complication limiting the efficacy of the treatment. A variety of renal disease and electrolyte disorders can result from the drugs that are used to treat malignant disease. The kidneys are a major elimination pathway for many antineoplastic drugs and their metabolites. Tumour lysis syndrome, an emergency in haematooncology, occurs most often after the initiation of cytotoxic therapy in patients with high-grade lymphomas and acute lymphoblastic leukaemia. Chemotherapeutic agents can affect the glomerulus, tubules, interstitium and renal microvasculature, with clinical manifestations that range from asymptomatic elevation of serum creatinine to acute renal failure requiring dialysis. Some factors such as intravascular volume depletion, as well as concomitant use of other drugs or radiographic ionic contrast media, can potentiate or contribute to the nephrotoxicity. Cytotoxic agents can cause nephrotoxicity by a variety of mechanisms. The most nephrotoxic chemotherapeutic drug is cisplatin, which is often associated with acute kidney injury. Many other drugs such as alkylating agents, antimetabolites, vascular endothelial growth factor pathway inhibitors and epidermal growth factor receptor pathway inhibitors may have toxic effects on the kidneys. The aim of this review is to discuss the issue of nephrotoxicity associated with chemotherapy. In routine clinical practice, monitoring of kidney function is mandatory in order to identify nephrotoxicity early, allowing dosage adjustments or withdrawal of the offending drug.<\/jats:p>","DOI":"10.1093\/ndt\/gfw338","type":"journal-article","created":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T20:28:48Z","timestamp":1475785728000},"page":"924-936","source":"Crossref","is-referenced-by-count":71,"title":["Nephrotoxicity of anticancer treatment"],"prefix":"10.1093","volume":"32","author":[{"given":"Jolanta","family":"Ma\u0142yszko","sequence":"first","affiliation":[{"name":"Medical University in Bialystok 1 2nd Department of Nephrology and Hypertension with Dialysis Unit ,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"Koz\u0142owska","sequence":"additional","affiliation":[{"name":"Medical University in Bialystok 1 2nd Department of Nephrology and Hypertension with Dialysis Unit ,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Koz\u0142owski","sequence":"additional","affiliation":[{"name":"Ministry of Interior Affairs 2 Department of Oncological Surgery , Hospital, Bialystok ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Ma\u0142yszko","sequence":"additional","affiliation":[{"name":"Medical University in Bialystok 3 1st Department of Nephrology and Transplantology with Dialysis Unit , , Bia\u0142ystok ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,10,6]]},"reference":[{"key":"2025102312501623300_GFW338C1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1681\/ASN.2004100843","article-title":"Renal failure associated with cancer and its treatment: an update","volume":"16","author":"Humphreys","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2025102312501623300_GFW338C2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/ki.2012.484","article-title":"Glomerular diseases seen with cancer and chemotherapy: a narrative review","volume":"84","author":"Jhaveri","year":"2013","journal-title":"Kidney Int"},{"key":"2025102312501623300_GFW338C3","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/ki.2015.30","article-title":"New drug toxicities in the onco-nephrology world","volume":"87","author":"Perazella","year":"2015","journal-title":"Kidney Int"},{"key":"2025102312501623300_GFW338C4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.ackd.2013.08.003","article-title":"Glomerular diseases associated with cancer, chemotherapy, and hematopoietic stem cell transplantation","volume":"21","author":"Jhaveri","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"2025102312501623300_GFW338C5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/ki.2013.50","article-title":"Nephrology Crossword: Onco-nephrology\u2014chemotherapy agents and nephrotoxicity","volume":"84","author":"Jhaveri","year":"2013","journal-title":"Kidney Int"},{"key":"2025102312501623300_GFW338C6","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2215\/CJN.02780312","article-title":"Onco-nephrology: renal toxicities of chemotherapeutic agents","volume":"7","author":"Perazella","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312501623300_GFW338C7","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med"},{"key":"2025102312501623300_GFW338C8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0002-9343(93)90174-N","article-title":"Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma","volume":"94","author":"Hande","year":"1993","journal-title":"Am J Med"},{"key":"2025102312501623300_GFW338C9","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus","volume":"149","author":"Cairo","year":"2010","journal-title":"Br J Haematol"},{"key":"2025102312501623300_GFW338C10","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1158\/1078-0432.CCR-07-4793","article-title":"Interaction of Cisplatin with the human organic cation transporter 2","volume":"14","author":"Filipski","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2025102312501623300_GFW338C11","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/ki.1984.86","article-title":"Uptake and metabolism of cisplatin by rat kidney","volume":"25","author":"Safirstein","year":"1984","journal-title":"Kidney Int"},{"key":"2025102312501623300_GFW338C12","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0022-3565(25)32105-1","article-title":"Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations","volume":"213","author":"Dobyan","year":"1980","journal-title":"J Pharmacol Exp Ther"},{"key":"2025102312501623300_GFW338C13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/978-1-59259-963-9_63","article-title":"Recent progress in the pathophysiology of acute renal failure","volume-title":"Principles of Molecular Medicine","author":"Portilla","year":"2006","edition":"2nd edn"},{"key":"2025102312501623300_GFW338C14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.ndt.a091984","article-title":"Role of vascular congestion in cisplatin-induced acute renal failure in the rat","volume":"7","author":"Luke","year":"1992","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312501623300_GFW338C15","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1172\/JCI200215606","article-title":"TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity","volume":"110","author":"Ramesh","year":"2002","journal-title":"J Clin Invest"},{"key":"2025102312501623300_GFW338C16","doi-asserted-by":"crossref","first-page":"F166","DOI":"10.1152\/ajprenal.00401.2004","article-title":"p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice","volume":"289","author":"Ramesh","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025102312501623300_GFW338C17","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0022-3565(24)37859-0","article-title":"Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs","volume":"287","author":"Urakami","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"2025102312501623300_GFW338C18","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1021\/tx800061w","article-title":"Integrated pathway analysis of rat urine metabolic profiles and kidney transcriptomic profiles to elucidate the systems toxicology of model nephrotoxicants","volume":"21","author":"Xu","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"2025102312501623300_GFW338C19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.ASN.0000042803.28024.92","article-title":"Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells","volume":"14","author":"Townsend","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"2025102312501623300_GFW338C20","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1081\/DMR-100101947","article-title":"Oxidant mechanisms in toxic acute renal failure","volume":"31","author":"Baliga","year":"1999","journal-title":"Drug Metab Rev"},{"key":"2025102312501623300_GFW338C21","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/S0002-9440(10)61234-5","article-title":"Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2","volume":"167","author":"Ciarimboli","year":"2005","journal-title":"Am J Pathol"},{"key":"2025102312501623300_GFW338C22","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1681\/ASN.2015010079","article-title":"Three-dimensional morphology by multiphoton microscopy with clearing in a model of cisplatin-induced CKD","volume":"27","author":"Torres","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2025102312501623300_GFW338C23","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00280-005-1010-7","article-title":"Magnesium depletion enhances cisplatin-induced nephrotoxicity","volume":"56","author":"Lajer","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025102312501623300_GFW338C24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7326\/0003-4819-101-1-41","article-title":"Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy","volume":"101","author":"Jackson","year":"1984","journal-title":"Ann Intern Med"},{"key":"2025102312501623300_GFW338C25","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.08070715","article-title":"Long-term renal outcomes after cisplatin treatment","volume":"11","author":"Latcha","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312501623300_GFW338C26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12885-016-2271-8","article-title":"Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors","volume":"16","author":"Sato","year":"2016","journal-title":"BMC Cancer"},{"key":"2025102312501623300_GFW338C27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00280-016-2966-1","article-title":"Validity of new methods to evaluate renal function in cancer patients treated with cisplatin","volume":"77","author":"Funakoshi","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025102312501623300_GFW338C28","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/0002-9343(91)80022-E","article-title":"Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature","volume":"90","author":"McDonald","year":"1991","journal-title":"Am J Med"},{"key":"2025102312501623300_GFW338C29","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/1097-0142(19940215)73:4<1297::AID-CNCR2820730427>3.0.CO;2-#","article-title":"A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group","volume":"73","author":"Ettinger","year":"1994","journal-title":"Cancer"},{"key":"2025102312501623300_GFW338C30","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1681\/ASN.V1281615","article-title":"Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide","volume":"12","author":"Dubourg","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"2025102312501623300_GFW338C31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/157488506775268515","article-title":"Clinical pharmacology of cyclophosphamide and ifosfamide","volume":"1","author":"Zhang","year":"2006","journal-title":"Curr Drug Ther"},{"key":"2025102312501623300_GFW338C32","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/archinte.1985.00360030196034","article-title":"Water intoxication following moderate-dose intravenous cyclophosphamide","volume":"145","author":"Bressler","year":"1985","journal-title":"Arch Intern Med"},{"key":"2025102312501623300_GFW338C33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1200\/JCO.1993.11.1.173","article-title":"Ifosfamide, mesna, and nephrotoxicity in children","volume":"11","author":"Skinner","year":"1993","journal-title":"J Clin Oncol"},{"key":"2025102312501623300_GFW338C34","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1200\/JCO.2008.17.5257","article-title":"Long-term evaluation of Ifosfamide-related nephrotoxicity in children","volume":"27","author":"Oberlin","year":"2009","journal-title":"J Clin Oncol"},{"key":"2025102312501623300_GFW338C35","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.ejca.2012.03.009","article-title":"Long term renal toxicity of ifosfamide in adult patients-5 year data","volume":"48","author":"Farry","year":"2012","journal-title":"Eur J Cancer"},{"key":"2025102312501623300_GFW338C36","first-page":"556","article-title":"The nephrotoxicity of chemotherapeutic agents","volume":"10","author":"Narins","year":"1990","journal-title":"Semin Nephrol"},{"key":"2025102312501623300_GFW338C37","doi-asserted-by":"crossref","first-page":"108","DOI":"10.7326\/0003-4819-79-1-108","article-title":"Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients","volume":"79","author":"Broder","year":"1973","journal-title":"Ann Intern Med"},{"key":"2025102312501623300_GFW338C38","doi-asserted-by":"crossref","first-page":"122","DOI":"10.7326\/0003-4819-96-1-122_1","article-title":"Nephrotoxicity of streptozocin","volume":"96","author":"Perry","year":"1982","journal-title":"Ann Intern Med"},{"key":"2025102312501623300_GFW338C39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00002018-200124010-00003","article-title":"Anticancer drug-induced kidney disorders","volume":"24","author":"Kintzel","year":"2001","journal-title":"Drug Saf"},{"key":"2025102312501623300_GFW338C40","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0272-6386(97)90042-1","article-title":"Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy","volume":"29","author":"Groff","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"2025102312501623300_GFW338C41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF00262421","article-title":"High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach","volume":"3","author":"Monjanel","year":"1979","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025102312501623300_GFW338C42","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","article-title":"Understanding and managing methotrexate nephrotoxicity","volume":"11","author":"Widemann","year":"2006","journal-title":"Oncologist"},{"key":"2025102312501623300_GFW338C43","first-page":"1389","article-title":"Changes in glomerular filtration rate associated with high-dose methotrexate therapy in adults","volume":"61","author":"Howell","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"2025102312501623300_GFW338C44","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/cncr.20255","article-title":"High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma","volume":"100","author":"Widemann","year":"2004","journal-title":"Cancer"},{"key":"2025102312501623300_GFW338C45","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3109\/0886022X.2010.501930","article-title":"Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed","volume":"32","author":"Stavroulopoulos","year":"2010","journal-title":"Ren Fail"},{"key":"2025102312501623300_GFW338C46","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1385\/MO:23:3:419","article-title":"Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer","volume":"23","author":"Vootukuru","year":"2006","journal-title":"Med Oncol"},{"key":"2025102312501623300_GFW338C47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40620-014-0117-5","article-title":"Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer reversible and chronic renal damage","volume":"28","author":"Rombol\u00e0","year":"2015","journal-title":"J Nephrol"},{"key":"2025102312501623300_GFW338C48","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1053\/j.ajkd.2011.04.030","article-title":"Kidney tubular toxicity of maintenance pemetrexed therapy","volume":"58","author":"Glezerman","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"2025102312501623300_GFW338C49","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1517\/14740330902942299","article-title":"Thrombotic microangiopathy associated with gemcitabine: rare but real","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"2025102312501623300_GFW338C50","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1179\/1973947813Y.0000000122","article-title":"Gemcitabine-related thrombotic microangiopathy: a single-centre retrospective series","volume":"26","author":"Leal","year":"2014","journal-title":"J Chemother"},{"key":"2025102312501623300_GFW338C51","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1182\/blood-2007-11-124602","article-title":"A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"112","author":"Faderl","year":"2008","journal-title":"Blood"},{"key":"2025102312501623300_GFW338C52","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/1078155213504976","article-title":"Clofarabine-induced kidney toxicity","volume":"20","author":"Jhaveri","year":"2014","journal-title":"J Oncol Pharm Pract"},{"key":"2025102312501623300_GFW338C53","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1634\/theoncologist.2010-0070","article-title":"Lenalidomide-induced acute interstitial nephritis","volume":"15","author":"Lipson","year":"2010","journal-title":"Oncologist"},{"key":"2025102312501623300_GFW338C54","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1080\/10428190802023707","article-title":"Azotemia associated with use of lenalidomide in plasma cell dyscrasias","volume":"49","author":"Batts","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"2025102312501623300_GFW338C55","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1078155214568581","article-title":"A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use","volume":"22","author":"Baird","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"2025102312501623300_GFW338C56","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0002-9343(71)90244-0","article-title":"Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy","volume":"51","author":"Cutting","year":"1971","journal-title":"Am J Med"},{"key":"2025102312501623300_GFW338C57","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1345\/aph.17278","article-title":"Syndrome of inappropriate antidiuretic hormone associated with vinorelbine therapy","volume":"32","author":"Garrett","year":"1998","journal-title":"Ann Pharmacother"},{"key":"2025102312501623300_GFW338C58","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/00043426-200009000-00024","article-title":"Hemolytic uremic syndrome secondary to the treatment of acute lymphoblastic leukemia","volume":"22","author":"Kanchi","year":"2000","journal-title":"J Pediatr Hematol Oncol"},{"key":"2025102312501623300_GFW338C59"},{"key":"2025102312501623300_GFW338C60","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/leu.2013.29","article-title":"Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety","volume":"27","author":"Badros","year":"2013","journal-title":"Leukemia"},{"key":"2025102312501623300_GFW338C61","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2008.131","article-title":"Pathogenesis and treatment of renal failure in multiple myeloma","volume":"22","author":"Dimopoulos","year":"2008","journal-title":"Leukemia"},{"key":"2025102312501623300_GFW338C62","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1471-2369-15-156","article-title":"Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma","volume":"15","author":"Hobeika","year":"2014","journal-title":"BMC Nephrol"},{"key":"2025102312501623300_GFW338C63","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1002\/phar.1397","article-title":"Carfilzomib-associated tumor lysis syndrome","volume":"34","author":"Shely","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"(Suppl 3)","key":"2025102312501623300_GFW338C64","first-page":"19","article-title":"Incidence and management of renal adverse events in patients with relapsed and\/or refractory multiple myeloma treated with single-agent carfilzomib","volume":"27","author":"Shah","year":"2013","journal-title":"Oncology (Williston Park)"},{"key":"2025102312501623300_GFW338C65","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/annonc\/mdv136","article-title":"Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN)","volume":"26","author":"Launay-Vacher","year":"2015","journal-title":"Ann Oncol"},{"key":"2025102312501623300_GFW338C66","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"58","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"2025102312501623300_GFW338C67","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CAD.0b013e3283161012","article-title":"Hypertension and proteinuria: a class-effect of antiangiogenic therapies","volume":"20","author":"Launay-Vacher","year":"2009","journal-title":"Anticancer Drugs"},{"key":"2025102312501623300_GFW338C68","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/j.ejca.2011.07.014","article-title":"Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell carcinoma","volume":"47","author":"Tomita","year":"2011","journal-title":"Eur J Cancer"},{"key":"2025102312501623300_GFW338C69","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2025102312501623300_GFW338C70","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/02841860802314720","article-title":"Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis","volume":"48","author":"Zhu","year":"2009","journal-title":"Acta Oncol"},{"key":"2025102312501623300_GFW338C71","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2146\/ajhp080455","article-title":"Understanding and managing the possible adverse effects associated with bevacizumab","volume":"66","author":"Shord","year":"2009","journal-title":"Am J Health Syst Pharm"},{"issue":"(Suppl)","key":"2025102312501623300_GFW338C72","article-title":"Results of the MARS study on the management of antiangiogenics\u2019 renovascular safety in ovarian cancer. American Society of Clinical Oncology Annual Meeting","volume":"31","author":"Launay-Vacher","year":"2013","journal-title":"J Clin Oncol"},{"issue":"(Suppl 2)","key":"2025102312501623300_GFW338C73","first-page":"S819","article-title":"Results of the MARS study on the management of antiangiogenics\u2019 renovascular safety in lung cancer","volume":"49","author":"Goldwasser","year":"2013","journal-title":"Eur J Cancer"},{"issue":"(24 Suppl)","key":"2025102312501623300_GFW338C74","first-page":"P3","article-title":"Results of the MARS study on the management of antiangiogenics\u2019 renovascular safety in breast cancer","volume":"73","author":"Gligorov","year":"2013","journal-title":"Cancer Res"},{"key":"2025102312501623300_GFW338C75","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur J Cancer"},{"key":"2025102312501623300_GFW338C76","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1681\/ASN.2010020167","article-title":"Bevacizumab increases risk for severe proteinuria in cancer patients","volume":"21","author":"Wu","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2025102312501623300_GFW338C77","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"key":"2025102312501623300_GFW338C78","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1053\/j.ajkd.2006.11.024","article-title":"Nephrotic syndrome after bevacizumab: case report and literature review","volume":"49","author":"George","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2025102312501623300_GFW338C79","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"2025102312501623300_GFW338C80","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"2025102312501623300_GFW338C81","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/jnci\/djm311","article-title":"A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib","volume":"100","author":"Patel","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"2025102312501623300_GFW338C82","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/annonc\/mdv136","article-title":"Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN)","volume":"26","author":"Humphreys","year":"2015","journal-title":"Ann Oncol"},{"key":"2025102312501623300_GFW338C83","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.111.173559","article-title":"The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system","volume":"58","author":"Kappers","year":"2011","journal-title":"Hypertension"},{"key":"2025102312501623300_GFW338C84","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/ndt\/gft465","article-title":"All anti-vascular endothelial growth factor drugs can induce \u2018pre-eclampsia-like syndrome\u2019: a RARe study","volume":"29","author":"Vigneau","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312501623300_GFW338C85","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc072330","article-title":"Home blood-pressure monitoring in patients receiving sunitinib","volume":"358","author":"Azizi","year":"2008","journal-title":"N Engl J Med"},{"key":"2025102312501623300_GFW338C86","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.humpath.2014.05.015","article-title":"Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature","volume":"45","author":"Usui","year":"2014","journal-title":"Hum Pathol"},{"key":"2025102312501623300_GFW338C87","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1210\/jc.2009-2461","article-title":"Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"95","author":"Robinson","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2025102312501623300_GFW338C88","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","article-title":"Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"28","author":"Wells","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025102312501623300_GFW338C89","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(07)70108-0","article-title":"Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study","volume":"8","author":"Tejpar","year":"2007","journal-title":"Lancet Oncol"},{"key":"2025102312501623300_GFW338C90","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(15)00021-2","article-title":"Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial","volume":"16","author":"Thatcher","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025102312501623300_GFW338C91","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11523-009-0109-x","article-title":"Renal toxicity of targeted therapies","volume":"4","author":"Kelly","year":"2009","journal-title":"Target Oncol"},{"key":"2025102312501623300_GFW338C92","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1172\/JCI31680","article-title":"Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia","volume":"117","author":"Groenestege","year":"2007","journal-title":"J Clin Invest"},{"key":"2025102312501623300_GFW338C93","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations in BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"2025102312501623300_GFW338C94","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1158\/2159-8290.CD-13-0014","article-title":"Targeting the BRAF V600E mutation in multiple myeloma","volume":"3","author":"Andrulis","year":"2013","journal-title":"Cancer Discov"},{"key":"2025102312501623300_GFW338C95","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"key":"2025102312501623300_GFW338C96","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/107327481402100307","article-title":"BRAF mutations: signaling, epidemiology and clinical experience in multiple malignancies","volume":"21","author":"Hall","year":"2014","journal-title":"Cancer Control"},{"key":"2025102312501623300_GFW338C97","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ckj\/sfv149","article-title":"Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network","volume":"9","author":"Wanchoo","year":"2016","journal-title":"Clin Kidney J"},{"key":"2025102312501623300_GFW338C98","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/cncr.28709","article-title":"Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients","volume":"120","author":"Launay-Vacher","year":"2014","journal-title":"Cancer"},{"key":"2025102312501623300_GFW338C99","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaoncol.2015.1713","article-title":"Nephrotoxicity of the BRAF inhibitors vemurafenib and dabrafenib","volume":"1","author":"Jhaveri","year":"2015","journal-title":"JAMA Oncol"},{"key":"2025102312501623300_GFW338C100","doi-asserted-by":"crossref","first-page":"F93","DOI":"10.1152\/ajprenal.00345.2007","article-title":"Identification of BRAF as a new interactor of PLCepsilon1, the protein mutated in nephrotic syndrome type 3","volume":"294","author":"Chaib","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025102312501623300_GFW338C101","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cncr.28478","article-title":"Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib","volume":"120","author":"Brosnan","year":"2014","journal-title":"Cancer"},{"key":"2025102312501623300_GFW338C102","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1097\/JTO.0000000000000321","article-title":"Crizotinib effects on creatinine and non-creatinine-based measures of glomerular filtration rate","volume":"9","author":"Camidge","year":"2014","journal-title":"J Thorac Oncol"},{"key":"2025102312501623300_GFW338C103","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.lungcan.2013.08.007","article-title":"Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma","volume":"82","author":"Gastaud","year":"2013","journal-title":"Lung Cancer"},{"key":"2025102312501623300_GFW338C104","doi-asserted-by":"crossref","first-page":"428","DOI":"10.5114\/aoms.2016.59270","article-title":"Cardiotoxicity of anthracycline therapy: current perspectives","volume":"12","author":"Valcovici","year":"2016","journal-title":"Arch Med Sci"},{"issue":"(Suppl 15)","key":"2025102312501623300_GFW338C105","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1053\/j.seminoncol.2006.04.022","article-title":"Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer","volume":"33","author":"Jensen","year":"2006","journal-title":"Semin Oncol"},{"key":"2025102312501623300_GFW338C106","doi-asserted-by":"crossref","first-page":"371","DOI":"10.5114\/aoms.2015.50969","article-title":"The influence of steroid receptor status on the cardiotoxicity risk in HER2-positive breast cancer patients receiving trastuzumab","volume":"11","author":"Huszno","year":"2015","journal-title":"Arch Med Sci"},{"key":"2025102312501623300_GFW338C107","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11739-012-0794-9","article-title":"Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer","volume":"7","author":"Russo","year":"2012","journal-title":"Intern Emerg Med"},{"key":"2025102312501623300_GFW338C108","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11739-012-0845-2","article-title":"Renal dysfunction and increased risk of cardiotoxicity with trastuzumab therapy: a new challenge in cardio-oncology","volume":"7","author":"Albini","year":"2012","journal-title":"Intern Emerg Med"},{"key":"2025102312501623300_GFW338C109","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1200\/JCO.2009.21.9709","article-title":"First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the herceptin, cyclophosphamide and epirubicin (HERCULES) trial","volume":"28","author":"Untch","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025102312501623300_GFW338C110","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"2025102312501623300_GFW338C111","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025102312501623300_GFW338C112","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"2025102312501623300_GFW338C113","first-page":"287","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"68","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"2025102312501623300_GFW338C114","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2025102312501623300_GFW338C115","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10637-014-0092-7","article-title":"Kidney injuries related to ipilimumab","volume":"32","author":"Izzedine","year":"2014","journal-title":"Invest New Drugs"},{"key":"2025102312501623300_GFW338C116","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"},{"key":"2025102312501623300_GFW338C117","first-page":"4607","article-title":"Ipilimumab-induced immune-related renal failure\u2014a case report","volume":"32","author":"Forde","year":"2012","journal-title":"Anticancer Res"},{"key":"2025102312501623300_GFW338C118","doi-asserted-by":"crossref","first-page":"e537","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One"},{"key":"2025102312501623300_GFW338C119","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1200\/JCO.2010.32.2206","article-title":"Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy","volume":"29","author":"Chmiel","year":"2011","journal-title":"J Clin Oncol"},{"key":"2025102312501623300_GFW338C120","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"2025102312501623300_GFW338C121","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3109\/07357907.2013.789900","article-title":"Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I\/II trial of the SCRI oncology research consortium","volume":"31","author":"Hainsworth","year":"2013","journal-title":"Cancer Invest"},{"key":"2025102312501623300_GFW338C122","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J Clin Oncol"},{"key":"2025102312501623300_GFW338C123","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/CAD.0000000000000253","article-title":"Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma","volume":"26","author":"Nouhaud","year":"2015","journal-title":"Anticancer Drugs"},{"key":"2025102312501623300_GFW338C124","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000201930","article-title":"Temsirolimus-induced glomerulopathy","volume":"76","author":"Izzedine","year":"2009","journal-title":"Oncology"},{"key":"2025102312501623300_GFW338C125","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025102312501623300_GFW338C126","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<247::AID-AJH9>3.0.CO;2-T","article-title":"Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia","volume":"62","author":"Yang","year":"1999","journal-title":"Am J Hematol"},{"key":"2025102312501623300_GFW338C127","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s002770050419","article-title":"Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)","volume":"77","author":"Jensen","year":"1998","journal-title":"Ann Hematol"},{"key":"2025102312501623300_GFW338C128","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1200\/JCO.1994.12.12.2714","article-title":"Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma","volume":"12","author":"Guleria","year":"1994","journal-title":"J Clin Oncol"},{"key":"2025102312501623300_GFW338C129","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/bmj.290.6476.1180","article-title":"Nephrotic syndrome during treatment with interferon","volume":"290","author":"Selby","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2025102312501623300_GFW338C130","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00005792-200207000-00008","article-title":"Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature","volume":"81","author":"Zuber","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"2025102312501623300_GFW338C131","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1159\/000368844","article-title":"Side effects of bone-targeted therapies in advanced breast cancer","volume":"9","author":"Domschke","year":"2014","journal-title":"Breast Care (Basel)"},{"key":"2025102312501623300_GFW338C132","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1200\/JOP.2011.000486","article-title":"Acute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) project","volume":"9","author":"Edwards","year":"2013","journal-title":"J Oncol Pract"},{"key":"2025102312501623300_GFW338C133","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2014-1001","article-title":"Denosumab for treatment of hypercalcemia of malignancy","volume":"99","author":"Hu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2025102312501623300_GFW338C134","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"2025102312501623300_GFW338C135","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025102312501623300_GFW338C136","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","article-title":"Hypocalcaemia in patients with metastatic bone disease treated with denosumab","volume":"51","author":"Body","year":"2015","journal-title":"Eur J Cancer"},{"key":"2025102312501623300_GFW338C137","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"},{"key":"2025102312501623300_GFW338C138","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"2025102312501623300_GFW338C139","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","article-title":"Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate","volume":"12","author":"Markowitz","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"2025102312501623300_GFW338C140","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1053\/j.ajkd.2006.02.189","article-title":"Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept?","volume":"47","author":"Sauter","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2025102312501623300_GFW338C141","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/ndt\/gfg567","article-title":"Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient","volume":"19","author":"Kunin","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312501623300_GFW338C142","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1186\/s12885-015-1536-y","article-title":"Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature","volume":"15","author":"Jia","year":"2015","journal-title":"BMC Cancer"},{"key":"2025102312501623300_GFW338C143","doi-asserted-by":"crossref","first-page":"263","DOI":"10.5414\/CNP67263","article-title":"Potential effect of zoledronate therapy in heavy proteinuria","volume":"67","author":"Gokden","year":"2007","journal-title":"Clin Nephrol"},{"key":"2025102312501623300_GFW338C144","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"2025102312501623300_GFW338C145","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1523-1755.2004.00426.x","article-title":"Podocyte injury associated glomerulopathies induced by pamidronate","volume":"65","author":"Barri","year":"2004","journal-title":"Kidney Int"},{"key":"2025102312501623300_GFW338C146","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int"},{"key":"2025102312501623300_GFW338C147","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000322043","article-title":"Bisphosphonates in breast cancer patients with bone metastases","volume":"5","author":"Diel","year":"2010","journal-title":"Breast Care"},{"key":"2025102312501623300_GFW338C148","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1093\/ndt\/gfm209","article-title":"Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient","volume":"22","author":"Bodmer","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312501623300_GFW338C149","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.semnephrol.2007.02.004","article-title":"Functions of TNF and its receptors in renal disease: distinct roles in inflammatory tissue injury and immune regulation","volume":"27","author":"Vielhauer","year":"2007","journal-title":"Semin Nephrol"},{"key":"2025102312501623300_GFW338C150","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.kint.2016.06.027","article-title":"Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration Adverse Event Reporting System","volume":"90","author":"Jhaveri","year":"2016","journal-title":"Kidney Int"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/32\/6\/924\/17701412\/gfw338.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/32\/6\/924\/17701412\/gfw338.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:51:36Z","timestamp":1761238296000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/32\/6\/924\/3059468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,6]]},"references-count":150,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,10,6]]},"published-print":{"date-parts":[[2017,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfw338","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,6]]},"published":{"date-parts":[[2016,10,6]]}}}